Hoth Therapeutics filed patents to address skin toxicities from cancer therapies, focusing on HT-001's neurogenic and inflammatory pathway targeting. The patents aim to secure intellectual property ...
“Refiling a provisional is just a bad idea when you can, for a few hundred dollars more, keep hold of that earliest priority date and continue on the path to obtaining a patent.” The question that we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback